Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

Denmark’s benchmark stock index has fallen 21% from its September high, making it the first major European index to enter a bear market as tariff-related risks and a slump for Novo Nordisk A/S weigh.

Both CagriSema and retatrutide are set to seek regulatory approval in the first quarter of 2026. Price cuts in the most popular weight-loss drug Despite recent setbacks, Novo Nordisk’s latest ...

Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.